Please use this identifier to cite or link to this item:
https://hdl.handle.net/10923/904
Type: | article |
Title: | Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats |
Author(s): | Maahs, Márcia Angélica Peter Azambuja, Alan Arrieira Campos, Maria Martha Salum, Fernanda Gonçalves Cherubini, Karen |
Publisher: | Wiley Periodicals, Inc |
Issue Date: | 2011 |
Volume: | 33 |
Issue: | 2 |
First page: | 199 |
Last page: | 207 |
Keywords: | BISPHOSPHONATES JAW OSTEONECROSIS ANGIOGENESIS ZOLEDRONIC ACID ALENDRONATE ODONTOLOGIA OSSOS - NECROSE |
Abstract: | BACKGROUND: This work aimed at determining whether bisphosphonate therapy produces a sufficient condition for jaw osteonecrosis after tooth extraction. METHODS: Rats were allocated into 3 groups: (1) 11 rats treated with alendronate, (2) 10 rats treated with zoledronic acid, and (3) 10 control rats. The animals were subjected to tooth extractions, and at the end of bisphosphonate therapy, they were humanely killed. Histologic sections of the surgical site were processed and analyzed. RESULTS: The zoledronic acid group showed higher incidences of osteonecrosis, inflammatory infiltrate, and microorganisms. There was no significant difference for epithelial or connective tissue, root fragments, vital bone, and positive staining for vascular endothelial growth factor (VEGF) among the groups. CONCLUSION: Zoledronic acid is associated with jaw osteonecrosis, whereas alendronate did not produce a condition sufficient for osteonecrosis after tooth extraction. Neither zoledronic acid nor alendronate was associated with a reduced immunohistochemical expression of VEGF in vital bone at the tooth extraction site. |
URI: | http://hdl.handle.net/10923/904 |
DOI: | 10.1002/hed.21422 |
PMID: | 20848442 |
ISSN: | 1043-3074 |
Appears in Collections: | Artigo de Periódico
|
All Items in PUCRS Repository are protected by copyright, with all rights reserved, and are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Read more.